[1] K. Eechoute, A. Sparreboom, H. Burger, R. M. Franke, G. Schiavon, J. Verweij, W. J. Loos, E. A. Wiemer, R. H. Mathijssen, "Drug transporters and imatinib treatment: Implications for clinical practice," Clin. Cancer Res. 17(3), 406–415 (2011).
[2] A. Petain, D. Kattygnarath, J. Azard, E. Chatelut, C. Delbaldo, B. Geoerger, M. Barrois, S. Seronie- Vivien, A. LeCesne, G. Vassal, "Population pharmacokinetics and pharmacogenetics of imatinib in children and adults," Clin. Cancer Res. 14(21), 7102–7109 (2008).
[3] S. Picard, K. Titier, G. Etienne, E. Teilhet, D. Ducint, M. A. Bernard, R. Lassalle, G. Marit, J. Reiffers, B. Begaud, N. Moore, M. Molimard, F. X. Mahon, "Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia," Blood 109(8), 3496–3499 (2007).
[4] C. Delbaldo, E. Chatelut, M. Re, A. Deroussent, S. Seronie-Vivien, A. Jambu, P. Berthaud, A. Le Cesne, J.-Y. Blay, G. Vassal, "Pharmacokinetic- Pharmacodynamic relationships of imatinib and its main metabolite in patients with advanced gastrointestinal stromal tumors," Clin. Cancer Res. 12(20), 6073–6078 (2006).
[5] S. Bouchet, B. Royer, C. Le Guellec, K. Titier, "Therapeutic drug monitoring of tyrosine-kinase inhibitors in the treatment of chronic myelogenous leukaemia: Interests and limits," Therapie 65(3), 213–218 (2010).
[6] T. P. Hughes, S. Branford, "Monitoring disease response to tyrosine kinase inhibitor therapy in CML," Hematology 1, 477–487 (2009).
[7] M. Miura, N. Takahashi, K. Sawada, "Quantitative determination of imatinib in human plasma with high performance liquid chromatography and ultraviolet detection," J. Chromatogr. Sci. 49(5), 412–415 (2011).
[8] R. S. Golightly, W. E. Doering, M. J. Natan, "Surface-enhanced Raman spectroscopy and homeland security: A perfect match ," ACS Nano 3(10), 2859–2869 (2009).
[9] Q. Tu, C. Chang, "Diagnostic applications of Raman spectroscopy," Nanomedicine 8(5), 545–558 (2012).
[10] S. Wartewig, R. H. Neubert, "Pharmaceutical applications of mid-IR and Raman spectroscopy," Adv. Drug Deliv. Rev. 57(8), 1144–1170 (2005).
[11] N. C. Dingari, G. L. Horowitz, J. W. Kang, R. R. Dasari, I. Barman, "Raman spectroscopy provides a powerful diagnostic tool for accurate determination of albumin glycation," PLoS One 7(2), e32406 (2012).
[12] J. Filik, N. Stone, "Drop coating deposition Raman spectroscopy of protein mixtures," Analyst 132, 544–550 (2007).
[13] D. Zhang, Y. Xie, M. F. Mrozek, C. Ortiz, V. J. Davisson, D. Ben-Amotz, "Raman detection of proteomic analytes," Anal. Chem. 75(21), 5703– 5709 (2003).
[14] K. Kneipp, Y. Wang, H. Kneipp, L. T. Perelman, I. Itzkan, R. R. Dasari, M. S. Feld, "Single molecule detection using surface-enhanced Raman scattering (SERS)," Phys. Rev. Lett. 78, 1667 (1997).
[15] W. Xie, S. Schlucker, "Medical applications of surface- enhanced Raman scattering," Phys. Chem. Chem. Phys. 15(15), 5329–5344 (2013).
[16] A. Sahu, K. Dalal, S. Naglot, P. Aggarwal, C. M. Krishna, "Serum based diagnosis of asthma using Raman spectroscopy: An early phase pilot study," PLoS One 8(11), e78921 (2013).
[17] J. Zhang, M. R. Langille, M. L. Personick, K. Zhang, S. Li, C. A. Mirkin, "Concave cubic gold nanocrystals with high-index facets," J. Am. Chem. Soc. 132, 14012–14014 (2010).
[18] Y. P. de León, J. Pichardo-Molina, N. A. Ochoa, "Growth kinetics of concave nanocubes studied by optical coherence tomography," Plasmonics 9, 907–915 (2014).
[19] A. Srivastava, B. Joshi, P. Tandon, A. Ayala, A. Bansal, D. Grillo, "Study of polymorphism in imatinib mesylate: A quantum chemical approach using electronic and vibrational spectra," Spectrochim. Acta A 103, 325–332 (2013).
[20] F. S. Parker, Applications of Infrared, Raman and Resonance Raman spectroscopy in Biochemistry, Plenum Press, New York and London (1983).
